Board appointment at Molecular Partners
This article was originally published in Scrip
Executive Summary
Molecular Partners (Switzerland), a privately held biotech company focused on a class of biological drugs, known as DARPins, as next-generation protein therapeutics, has appointed Dr Göran Ando as an independent non-executive board member. He is currently vice-chairman of the board of directors at Novo Nordisk and a senior advisor to Essex Woodlands Health Ventures..